Highlights

Sai Life Sciences seeks top scientists. Expansion in advanced drug modalities. Major R&D recruitment drive.

Latest news

Emma Roberts to return for 'Aquamarine' TV series 20 years after original film

Emma Roberts to return for 'Aquamarine' TV series 20 years after original film

IBM unveils first sub-1 nm chip; Packs nearly 100 bn transistors into a space the size of fingernail

IBM unveils first sub-1 nm chip; Packs nearly 100 bn transistors into a space the size of fingernail

ZTE Showcases Full-Stack AI Capabilities at MWC Shanghai 2026, Empowering New Era of Token Operations

ZTE Showcases Full-Stack AI Capabilities at MWC Shanghai 2026, Empowering New Era of Token Operations

Tailorworks Introduces a Modern Approach to Bespoke Fashion for Today's Luxury Consumer

Tailorworks Introduces a Modern Approach to Bespoke Fashion for Today's Luxury Consumer

Zoey Deutch says having two Taylor Swift songs in 'Voicemails For Isabelle' "meant a lot" to her

Zoey Deutch says having two Taylor Swift songs in 'Voicemails For Isabelle' "meant a lot" to her

PNB MetLife records 99.81 percent Individual Claim Settlement Ratio in FY26

PNB MetLife records 99.81 percent Individual Claim Settlement Ratio in FY26

"India-Israel FTA may be signed in very near future": Israel Embassy's Economic Division head Ofir Amami

"India-Israel FTA may be signed in very near future": Israel Embassy's Economic Division head Ofir Amami

When Should You Review Your Term Life Insurance Policy?

When Should You Review Your Term Life Insurance Policy?

Sai Life Sciences Announces Talent Acquisition Campaign to Augment Process and Analytical R&D Leadership Capacity

Sai Life Sciences is expanding its R&D capabilities by recruiting experts in novel drug modalities like peptides and ADCs as part of its FY27 growth strategy, highlighting its leadership in India's CRDMO sector.

Sai Life Sciences Announces Talent Acquisition Campaign to Augment Process and Analytical R&D Leadership Capacity

BusinessWire India
Hyderabad (Telangana) [India], June 26: Sai Life Sciences (BSE: 544306 I NSE: SAILIFE), one of India's fastest growing, innovator-focused Contract Research, Development and Manufacturing Organizations (CRDMOs), today announced plans to strengthen its Process & Analytical R&D (PR&D and AR&D) capabilities through the recruitment of scientific team leaders and group leaders across multiple advanced modalities and technology platforms.
The hiring initiative forms part of the company's FY27 talent expansion plans and reflects the continued growth of its Chemistry, Manufacturing and Controls (CMC) business, as well as its commitment to building world-class scientific capabilities in emerging areas of drug development.
The company is seeking accomplished scientists and engineers with expertise in advanced modalities and enabling technologies, including peptides, antibody-drug conjugates (ADCs), oligonucleotides, flow chemistry, and analytical sciences.
"As the complexity of therapeutic modalities continues to evolve, scientific excellence becomes an even greater differentiator," said Krishna Kanumuri, MD & CEO, Sai Life Sciences. "We are investing not only in infrastructure and technology, but also in exceptional scientific talent. We are looking for scientists who are intellectually curious, passionate about solving difficult problems, and motivated by the opportunity to build capabilities that are among the best in the world."
The company is inviting applications from PhD-qualified scientists and chemical engineers with relevant industry experience, as well as from high-potential early-career PhDs / post-doctoral fellows. For leadership positions, Sai Life Sciences is seeking professionals with significant industry experience who have demonstrated technical depth, leadership potential, and a track record of delivering innovative solutions in pharmaceutical R&D. Interested candidates can apply here.
Successful candidates will have the opportunity to work with many of the world's leading pharmaceutical and biotechnology companies across a diverse portfolio of programs spanning small molecules, advanced modalities, and multiple therapeutic areas. They will benefit from advanced training, cross-functional exposure, and opportunities to work alongside experienced scientific leaders across disciplines.
The expansion further strengthens Sai Life Sciences' position at the forefront of India's rapidly evolving CRDMO sector. Over the past several years, the company has made significant investments in capabilities, infrastructure, and talent across the drug development value chain, supporting a growing number of global pharmaceutical and biotechnology innovators.
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)

(This article was generated from news agency ANI without modifications to the text.)

ADVERTISEMENT

Up Next

Sai Life Sciences Announces Talent Acquisition Campaign to Augment Process and Analytical R&D Leadership Capacity

Sai Life Sciences Announces Talent Acquisition Campaign to Augment Process and Analytical R&D Leadership Capacity

Step-by-step guide to apply for a mortgage loan online with minimal documentation

Step-by-step guide to apply for a mortgage loan online with minimal documentation

Honda Activa 6G: Everything You Need to Know Before Buying

Honda Activa 6G: Everything You Need to Know Before Buying

How much does a ULIP plan really cost? A break-down of all charges

How much does a ULIP plan really cost? A break-down of all charges

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Centre plans to borrow Rs 8.20 lakh cr from market in first half of FY27

Reliance denies buying Iranian oil amid US sanctions waiver

Reliance denies buying Iranian oil amid US sanctions waiver

ADVERTISEMENT

editorji-whatsApp

More videos

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

Premium petrol price up Rs 2, industrial diesel up Rs 22; no change in normal petrol, diesel rates

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

India's GDP expected to register over 8 pc growth in Sep-Dec: Report

Govt announces seven measures to help boost exports

Govt announces seven measures to help boost exports

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI keeps interest rates on hold after US trade deal boosts outlook

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI proposes to compensate customers up to Rs 25,000 loss due to fraud

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI raises GDP growth projection of Q1, Q2 of FY27

RBI pauses rate cuts, retains interest rate at 5.25 pc

RBI pauses rate cuts, retains interest rate at 5.25 pc

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Rupee jumps 122 paise to close at 90.27 against US dollar on India-US trade deal

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

Stock markets cheer India-US trade deal: Sensex, Nifty surge 2.5 pc

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

UPI transactions hit record high of Rs 230 lakh crore in 2025-26 till Dec: Govt

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.